


Company Presentation



Angelini
Pharma

UK11687P | May 2022



Who we are

Angelini started more than **100 years ago in Ancona, Italy** as a local pharmaceutical laboratory. Angelini Pharma is the pharmaceutical Company of the Angelini Group. The group's headquarters are now based in **Rome, Italy**.

We are an integrated pharma company with extensive **R&D programmes, world-class manufacturing** and **robust commercial capabilities**.

Angelini Pharma has a focus on supporting patients in **Mental Health, Pain Management, Central Nervous System (CNS), Rare Diseases and Consumer Healthcare**.

We aspire to become an **admired European innovator**, offering people, patients and their loved ones new medicines and solutions to achieve better health outcomes and **higher quality of life**.

Our history

1919 – 50 Beginnings

It all began in 1919 in Ancona, an Italian city on the shores of the Adriatic Sea. Here, Francesco Angelini set up a small pharmaceutical laboratory. Then in 1941, he founded ACRAF, (Aziende Chimiche Riunite Angelini Francesco), producing and distributing pharmaceuticals. In the aftermath of World War II, anaemia was a widespread problem in Italy. The company was the first to import a key treatment for this condition to Italy.

The 50s Transformation

At the start of the 1950s, activities were expanded to Rome where our headquarters are now located. The company also diversified into mass consumer goods. In 1958, Angelini Pharma launched an anti-flu drug. Today, it is the most frequently prescribed drug by paediatricians and one of the top three medicines sold in Italy.

1960 – 70 Growth

In these years, the first original molecules discovered by Angelini pharmaceutical research began production. A series of important and innovative molecules were discovered and developed in the 1960s and 1970s – medicines for cough, depression and glaucoma as well as anti-inflammatory medicines.

The 80s Expansion

Angelini Pharma started its international expansion by creating production facilities and commercial structures in Spain and Portugal. Angelini also built further manufacturing facilities in Italy producing medicines and pharmaceutical intermediates.

1990 – 2011 International

From the start of the new century, Angelini Pharma began a series of strategic acquisitions to reinforce its international footprint, first in the Iberian Peninsula and later in Central and Eastern Europe. Angelini Pharma also acquired leading global healthcare brands.

2012 – present Strategic focus

Angelini Pharma has continued its path of growth and internationalisation. Angelini Pharma has signed agreements with leading multinational pharmaceutical companies to market a wide range of medicines for mental health, pain and inflammation, and CNS disorders.



Key facts and figures



>€1B

sales +13% vs '19



25

countries where Angelini
Pharma is **directly present**



>70

countries where
our **products are marketed**



2,950

employees worldwide
+5% vs '19

Our worldwide team



52% men



48% women



49% men 51% women
in our first & second line
management roles



2,950
employees worldwide



>1,000
employees in sales



935
employees in manufacturing



>130
employees in R&D

Our ambition in Epilepsy

600,000

30%

One of the most common chronic neurological conditions is epilepsy, which affects 600,000 people in the UK.¹

30% of these patients remain resistant to medical treatments and so experience persistent seizures.¹

We know that seizure freedom is a key objective of epilepsy management² and so we aim to support people with epilepsy and their managing healthcare teams to achieve improved outcomes.

Thank you



Angelini
Pharma